Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : DB-3Q
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease
Details : DB-3Q is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Perianal Fistula-associated with Crohn Disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 09, 2025
Lead Product(s) : DB-3Q
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
Therapeutic Area : Gastroenterology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of ExoFlo for the Treatment of Perianal Fistulas
Details : ExoFlo (Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles) is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Rectal Fistula.
Product Name : ExoFlo
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 01, 2023
Lead Product(s) : Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ExoFlo
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DB-001 (ExoFlo) is a regenerative medicine product candidate, designed to leverage the anti-inflammatory, immunomodulatory and regenerative properties of bone marrow MSC-derived EVs. Currently in development for medically refractory perianal fistulizing ...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 26, 2023
Lead Product(s) : ExoFlo
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ExoFlo
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DB-001 (ExoFlo) is a regenerative medicine product candidate, designed to leverage the anti-inflammatory, immunomodulatory and regenerative properties of bone marrow MSC-derived EVs. Currently in development for treating severe or critical COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 19, 2023
Lead Product(s) : ExoFlo
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ExoFlo
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DB-001 (ExoFlo) is a regenerative medicine product candidate, designed to leverage the anti-inflammatory, immunomodulatory and regenerative properties of bone marrow MSC-derived EVs. Currently in development for treating severe or critical COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 21, 2023
Lead Product(s) : ExoFlo
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ExoFlo
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DB-001 (ExoFlo) is a regenerative medicine product candidate, designed to leverage the anti-inflammatory, immunomodulatory and regenerative properties of bone marrow MSC-derived EVs. Currently in development for treating severe or critical COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 14, 2023
Lead Product(s) : ExoFlo
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ExoFlo
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Good Works II Acquisition Corp.
Deal Size : $75.0 million
Deal Type : Agreement
Details : ExoFlo received regenerative medicine advanced therapy (“RMAT”) designation for the treatment of severe or critical COVID-19 from the U.S. Food and Drug Administration (“FDA”).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $75.0 million
October 13, 2022
Lead Product(s) : ExoFlo
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Good Works II Acquisition Corp.
Deal Size : $75.0 million
Deal Type : Agreement
Lead Product(s) : Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
Details : ExoFlo (Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles) is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Respiratory Distress Syndrome.
Product Name : ExoFlo
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
April 29, 2022
Lead Product(s) : Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DB-001,Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ExoFlo is an extracellular signal product isolated from human bone marrow MSCs that contains growth factors and extracellular vesicles including exosomes, to treat Acute Respiratory Distress Syndrome due to Covid-19.
Product Name : ExoFlo
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
April 21, 2022
Lead Product(s) : DB-001,Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Expanded Access for Use of ExoFlo in Abdominal Solid Organ Transplant Patients
Details : Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles is a Cell and Gene Therapy drug candidate, which is currently being evaluated in clinical studies for the treatment of Graft Rejection.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
January 31, 2022
Lead Product(s) : Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable